0.1
0.15
0.2
0.25
0.3
0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51 54 57 60 63 66 69 72 75 78 81 84 87 90
Absorbance@
590nm
Time(mins)
Glutamate
Malate
Isocitrate
Lactate
Co-culture PDAC tumor cells + CAFs respond to combination therapy of APX inhibition and metabolic inhibitor, CPI-613 (25 µM)
Arrows indicate treatment times.
0.00
0.20
0.40
0.60
0.80
1.00
1.20
1.40
1.60
1.80
4 8 12 14
Tumor Intensity Pa03C+CAF (n=3)
Ctrl CPI-613 APX3330 Combo
Days post plating
Fold
cha
nge
com
pare
d to
unt
reat
ed c
ontro
l
0.00
0.20
0.40
0.60
0.80
1.00
1.20
1.40
1.60
1.80
4 8 12 14
Tumor Intensity Pa03C+CAF (n=3)
Ctrl CPI-613 APX2009 Combo
APX3330=35 µM
Days post plating
APX2009=5 µM
-0.20
0.00
0.20
0.40
0.60
0.80
1.00
1.20
1.40
1.60
1.80
4 8 12 14
Tumor Intensity Pa03C+CAF (n=3)
Ctrl CPI-613 APX2014 Combo
Days post plating
APX2014=2.5 µM
Ctrl CPI-613 APX Combo
Co-culture PDAC tumor cells + CAFs respond to combination therapy of APX inhibition and metabolic inhibitor, CPI-613 (25 µM)
Arrows indicate treatment times.
0.00
0.20
0.40
0.60
0.80
1.00
1.20
1.40
1.60
1.80
4 8 12 14
Tumor Intensity Pa03C+CAF (n=3)
Ctrl CPI-613 APX3330 Combo
Days post plating
Fold
cha
nge
com
pare
d to
unt
reat
ed c
ontro
l
0.00
0.20
0.40
0.60
0.80
1.00
1.20
1.40
1.60
1.80
4 8 12 14
Tumor Intensity Pa03C+CAF (n=3)
Ctrl CPI-613 APX2009 Combo
APX3330=35 µM
Days post plating
APX2009=5 µM
-0.20
0.00
0.20
0.40
0.60
0.80
1.00
1.20
1.40
1.60
1.80
4 8 12 14
Tumor Intensity Pa03C+CAF (n=3)
Ctrl CPI-613 APX2014 Combo
Days post plating
APX2014=2.5 µM
Ctrl CPI-613 APX Combo
0
0.2
0.4
0.6
0.8
1
1.2
Day4 Day8 Day12
FoldCha
ngecompa
redtoSCR
G SCRG
SCRLowGSiGSiLowG
ScRNA-seq data of APE1 knockdown in normoxia and hypoxia
ScRNA-seq Differential Gene Expression Analysis
APEX1 Expression
Normoxia Hypoxia SCR SCR siAPE1 siAPE1
Fig 5: Validation of scRNA-seq in hypoxia. Expression of various Mitochondrial genes in normoxia and hypoxia, genes assessed via qRT-PCR in Pa03C cells. 3 independent experiments, showing average fold change +/- SD. *p